DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vesanoid (Tretinoin Oral) - Renal Failure - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Renal Failure (5)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vesanoid (Tretinoin Oral) where reactions include renal failure. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Vesanoid side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-03-22

Patient:

Reactions: Acute Promyelocytic Leukaemia Differentiation Syndrome, Guillain-Barre Syndrome, Haemorrhage, Pyrexia, Death, Renal Failure, Benign Intracranial Hypertension, Embolism, Neutropenia, Myocardial Infarction, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Vesanoid
    Dosage: induction: until complete remission or for maximum 45 days.
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: high risk: course 1: days 1-4.
    Indication: Acute Promyelocytic Leukaemia

Idarubicin Hydrochloride
    Dosage: consolidation therapy: course 3: on day 1

Idarubicin Hydrochloride
    Dosage: induction therapy: on days 2, 4, 6 and 8.
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: high risk: course 3: days 1-5

Etoposide
    Dosage: consolidation: high risk: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Vesanoid
    Dosage: consolidation therapy
    Administration route: Oral

Mitoxantrone Hydrochloride
    Dosage: consolidation: high and low/intermediate risk: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Thioguanine
    Dosage: consolidation: high risk: course 3: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Idarubicin Hydrochloride
    Dosage: consolidation course 1: on days 1, 2, 3 and 4

Other drugs received by patient: Prednisone TAB



Possible Vesanoid side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-03-18

Patient:

Reactions: Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Retinoic Acid Syndrome, Renal Failure, Benign Intracranial Hypertension, Embolism, Neutropenia, Myocardial Infarction, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Etoposide
    Dosage: consolidation: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: induction therapy: on days 2, 4, 6 and 8.
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: course 1: days 1-4.
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: course 3: days 1-5

Idarubicin HCL
    Dosage: consolidation course 1: on days 1, 2, 3 and 4

Vesanoid
    Dosage: induction: until complete remission or for maximum 45 days.
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: consolidation therapy: course 3: on day 1

Mitoxantrone Hydrochloride
    Dosage: consolidation: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Thioguanine
    Dosage: consolidation: course 3: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Other drugs received by patient: Prednisone



Possible Vesanoid side effects in

Reported by a individual with unspecified qualification from Italy on 2012-03-18

Patient:

Reactions: Guillain-Barre Syndrome, Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Benign Intracranial Hypertension, Renal Failure, Embolism, Neutropenia, Myocardial Infarction, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: consolidation: high risk: course 1: days 1-4.
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: high risk: course 3: days 1-5

Vesanoid
    Dosage: consolidation therapy
    Administration route: Oral

Thioguanine
    Dosage: consolidation: high risk: course 3: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Vesanoid
    Dosage: induction: until complete remission or for maximum 45 days.
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: consolidation course 1: on days 1, 2, 3 and 4

Idarubicin HCL
    Dosage: consolidation therapy: course 3: on day 1

Etoposide
    Dosage: consolidation: high risk: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone Hydrochloride
    Dosage: consolidation: high and low/intermediate risk: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: induction therapy: on days 2, 4, 6 and 8.
    Indication: Acute Promyelocytic Leukaemia

Other drugs received by patient: Prednisone



Possible Vesanoid side effects in

Reported by a individual with unspecified qualification from Italy on 2012-03-13

Patient:

Reactions: Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Retinoic Acid Syndrome, Benign Intracranial Hypertension, Renal Failure, Embolism, Neutropenia, Myocardial Infarction, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Idarubicin HCL
    Dosage: consolidation therapy: course 3: on day 1

Cytarabine
    Dosage: consolidation: course 3: days 1-5

Vesanoid
    Dosage: induction: until complete remission or for maximum 45 days.
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone Hydrochloride
    Dosage: consolidation: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: induction therapy: on days 2, 4, 6 and 8.
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: consolidation course 1: on days 1, 2, 3 and 4

Etoposide
    Dosage: consolidation: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: course 1: days 1-4.
    Indication: Acute Promyelocytic Leukaemia

Thioguanine
    Dosage: consolidation: course 3: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Other drugs received by patient: Prednisone



Possible Vesanoid side effects in

Reported by a individual with unspecified qualification from Italy on 2012-03-02

Patient:

Reactions: Guillain-Barre Syndrome, Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Benign Intracranial Hypertension, Renal Failure, Embolism, Neutropenia, Myocardial Infarction, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Vesanoid
    Dosage: consolidation therapy
    Administration route: Oral

Idarubicin Hydrochloride
    Dosage: consolidation therapy: course 3: on day 1

Idarubicin Hydrochloride
    Dosage: induction therapy: on days 2, 4, 6 and 8.
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: high risk: course 3: days 1-5

Idarubicin Hydrochloride
    Dosage: consolidation course 1: on days 1, 2, 3 and 4

Mitoxantrone Hydrochloride
    Dosage: consolidation: high and low/intermediate risk: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Thioguanine
    Dosage: consolidation: high risk: course 3: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Vesanoid
    Dosage: induction: until complete remission or for maximum 45 days.
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Cytarabine
    Dosage: consolidation: high risk: course 1: days 1-4.
    Indication: Acute Promyelocytic Leukaemia

Etoposide
    Dosage: consolidation: high risk: course 2: days 1-5
    Indication: Acute Promyelocytic Leukaemia

Other drugs received by patient: Prednisone TAB

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017